Innovative Medicine

Innovative Medicine

December 31, 2012

FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis

Innovative Medicine

December 27, 2012

New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1

New codes granted in recognition of clinical efficacy

Research

December 12, 2012

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

Innovative Medicine

December 12, 2012

CellSearch® ‘Liquid Biopsy’ Approved for Breast Cancer Patients in China

Innovative Medicine

December 12, 2012

The New England Journal of Medicine Publishes Efficacy Data for ZYTIGA® Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Not Received Chemotherapy

Data Supports This Week’s FDA Approval

Innovative Medicine

December 11, 2012

Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting

Data Show Overall Response of 68 Percent in Patients with Relapsed or Refractory Disease

Innovative Medicine

December 10, 2012

U.S. FDA Approves Expanded ZYTIGA® Indication For Treatment Of Metastatic Castration-Resistant Prostate Cancer

Innovative Medicine

December 10, 2012

FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients

Innovative Medicine

December 6, 2012

Janssen Submits Applications Requesting Approval Of STELARA® In U.S. And Europe For Treatment Of Active Psoriatic Arthritis